The Case for Cannabis & Psychedelic Stocks 😵‍💫

Are this alternative medicine stocks finally ready to hit their stride? Find out in this week's Insider Update.

There has been a flurry of new developments for various types of drugs used to treat mental health conditions, including LSD, MDMA, ketamine, and marijuana.

Shares of many of these companies could be poised to soar this year since the FDA recently elevated the status of many of these drugs. Shares of Mindmed [MNMD] have already soared over 100% YTD, and many others with exposure to these themes could deliver stellar gains this year.

The most recent developments from the FDA may support psychedelic companies focused on LSD. However, this more radical move from the FDA will likely have a spillover effect and positively impact companies that focus on other types of psychedelics and drugs as alternative mental health treatments. Many other drugs, such as ketamine and marijuana, are already popular alternative mental health treatment options.

2024 will likely be a very salient year for equities in this area, and plenty of publicly traded names could break out this year.

Catalysts Unleashed

Subscribe to Elite Trade Club Insider to read the rest.

Become a paying subscriber of Elite Trade Club Insider to get access to this post and other subscriber-only content.

Already a paying subscriber? Sign In

A subscription gets you:
Our Top Growth Stock Idea Every Month: These are our highest conviction stock picks that have the potential to 10x or more!
Exclusive Reports on the top AI, space and dividend stocks that could skyrocket in these emerging market.
Bi-Monthly Exclusive Market Insights: In-depth analysis of the key trends shaping the financial markets along with actionable insights.
Ad-Free Version of Our Daily Newsletter: Get all of the days trending stocks and market moving news without the ads!